Lung Cancer
From the Journals
Do some EGFR mutation subtypes benefit from immune checkpoint blockade?
One common EGFR tyrosine kinase inhibitor–sensitizing allele may be associated with similar benefit versus EGFR wild-type lung tumors, analysis...
From the Journals
Younger patients with NSCLC tend to live longer
According to a retrospective analysis, younger patients with NSCLC had better survival, despite higher rates of brain metastasis and drive...
How I will treat my next patient
PROs in lung cancer and how to administer trastuzumab
Dr. Alan P. Lyss explains what the PACIFIC and HannaH trials mean for your day-to-day practice.
Conference Coverage
Myc signaling, monocytes predict NSCLC response to second-line entinostat + pembro
ATLANTA – Investigators have identified factors associated with response to combination entinostat and pembrolizumab among NSCLC patients who...
Conference Coverage
SRA737 + anti–PD-L1 therapy and low-dose gemcitabine shows early promise for SCLC
ATLANTA – Preclinical data suggest a role for SRA737 plus anti–PD-L1 therapy and low-dose gemcitabine in SCLC.
Conference Coverage
MYSTIC trial: bTMB correlates with tTMB, predicts survival in mNSCLC
ATLANTA – Blood TMB predicts survival benefit in mNSCLC patients treated with first-line durvalumab plus tremelimumab versus chemo, according to...
Conference Coverage
Circulating tumor cells predict NSCLC survival, but clinical role uncertain
GENEVA - CTC counts of at least 5 cells per 7.5 mL were associated with reduced overall survival in a retrospective analysis involving 550...
Conference Coverage
PACIFIC: Patient-reported outcomes unaffected by PD-L1 expression
GENEVA – Level of programmed death-ligand 1 expression does not impact patient-reported outcomes among those...
Conference Coverage
Osimertinib again shows strength in NSCLC with leptomeningeal metastases
GENEVA – The overall response rate was 55% for patients with NSCLC and leptomeningeal metastases receiving...
Video
Dr. Douglas Paauw gives updates on antihypertensives, statins, SGLT2 inhibitors
PHILADELPHIA – This past year has been a tough one for ARBs.
From the Journals
First-line afatinib responses encouraging across diverse population of EGFR TKI-naive patients
GENEVA – The objective response rate was 46% in an interim analysis of EGFR TKI-naive patients with locally advanced...